Clinical Trials Logo

IDH2 Gene Mutation clinical trials

View clinical trials related to IDH2 Gene Mutation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04092179 Terminated - Clinical trials for Acute Myeloid Leukemia

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Start date: November 5, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood cancer). This study will also see how useful the combination of enasidenib and venetoclax is in the treatment of patients with relapsed or refractory AML.

NCT ID: NCT03303950 Terminated - Anemia Clinical Trials

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Start date: March 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.